170 related articles for article (PubMed ID: 19017257)
41. Partial thromboplastin time is more predictive of bleeding than anti-Xa levels in heparinized pediatric patients after cardiac surgery.
Oladunjoye OO; Sleeper LA; Nair AG; Trenor CC; VanderPluym C; Kheir JN; Emani SM
J Thorac Cardiovasc Surg; 2018 Jul; 156(1):332-340.e1. PubMed ID: 29709361
[TBL] [Abstract][Full Text] [Related]
42. Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin.
Mitsuguro M; Okamoto A; Shironouchi Y; Sano M; Miyata S; Neki R; Araki T; Hamamoto T; Yoshimatsu J; Miyata T
Int J Hematol; 2015 Feb; 101(2):119-25. PubMed ID: 25416968
[TBL] [Abstract][Full Text] [Related]
43. Monitoring of unfractionated heparin with the activated partial thromboplastin time: determination of therapeutic ranges.
van den Besselaar AM; Sturk A; Reijnierse GL
Thromb Res; 2002 Sep; 107(5):235-40. PubMed ID: 12479884
[TBL] [Abstract][Full Text] [Related]
44. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
[No Abstract] [Full Text] [Related]
45. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin.
van Roessel S; Middeldorp S; Cheung YW; Zwinderman AH; de Pont AC
Neth J Med; 2014 Jul; 72(6):305-10. PubMed ID: 25319855
[TBL] [Abstract][Full Text] [Related]
46. Accuracy, reproducibility and costs of different laboratory assays for the monitoring of unfractionated heparin in clinical practice: a prospective evaluation study and survey among Swiss institutions.
Bürki S; Brand B; Escher R; Wuillemin WA; Nagler M
BMJ Open; 2018 Jun; 8(6):e022943. PubMed ID: 29886450
[TBL] [Abstract][Full Text] [Related]
47. Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy.
Byun JH; Jang IS; Kim JW; Koh EH
Blood Res; 2016 Sep; 51(3):171-174. PubMed ID: 27722127
[TBL] [Abstract][Full Text] [Related]
48. [Correlation between aPTT and antifactor Xa to determine therapeutic ranges for unfractionated heparin].
Mariné L; Sánchez G; Vargas JF; Zúñiga P; Aizman A; Mertens R; Bergoeing M; Muñoz B
Rev Med Chil; 2014 Nov; 142(11):1392-7. PubMed ID: 25694284
[TBL] [Abstract][Full Text] [Related]
49. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children.
Kuhle S; Eulmesekian P; Kavanagh B; Massicotte P; Vegh P; Lau A; Mitchell LG
Haematologica; 2007 Apr; 92(4):554-7. PubMed ID: 17488668
[TBL] [Abstract][Full Text] [Related]
50. How to use unfractionated heparin to treat neonatal thrombosis in clinical practice.
Bhatt MD; Paes BA; Chan AK
Blood Coagul Fibrinolysis; 2016 Sep; 27(6):605-14. PubMed ID: 26656898
[TBL] [Abstract][Full Text] [Related]
51. Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation.
McGlasson DL; Kaczor DA; Krasuski RA; Campbell CL; Kostur MR; Adinaro JT
Blood Coagul Fibrinolysis; 2005 Apr; 16(3):173-6. PubMed ID: 15795534
[TBL] [Abstract][Full Text] [Related]
52. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization.
Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548
[TBL] [Abstract][Full Text] [Related]
53. Monitoring unfractionated heparin in children: a parallel-cohort randomized controlled trial comparing 2 dose protocols.
Hanslik A; Kitzmüller E; Tran US; Thom K; Karapetian H; Prutsch N; Voitl J; Michel-Behnke I; Newall F; Male C
Blood; 2015 Oct; 126(18):2091-7. PubMed ID: 26239090
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy.
McLaughlin K; Rimsans J; Sylvester KW; Fanikos J; Dorfman DM; Senna P; Connors JM; Goldhaber SZ
Clin Appl Thromb Hemost; 2019; 25():1076029619876030. PubMed ID: 31530176
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma.
Brooks MB
Vet Clin Pathol; 2004; 33(4):208-14. PubMed ID: 15570557
[TBL] [Abstract][Full Text] [Related]
56. Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?
Shin H; Koh EH; Lee GW; Song HN; Kim HY; Park S
J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):741-747. PubMed ID: 32113855
[TBL] [Abstract][Full Text] [Related]
57. Activated Partial Thromboplastin Time Versus Anti-Factor Xa Monitoring of Heparin Anticoagulation in Adult Venoarterial Extracorporeal Membrane Oxygenation Patients.
Kulig CE; Schomer KJ; Black HB; Dager WE
ASAIO J; 2021 Apr; 67(4):411-415. PubMed ID: 33769995
[TBL] [Abstract][Full Text] [Related]
58. Monitoring of unfractionated heparin using activated partial thromboplastin time: an assessment of the current nomogram and analysis according to age.
Kim JS; Lee HJ; Sung JD; Kim HJ; Lee SY; Kim JS
Clin Appl Thromb Hemost; 2014 Oct; 20(7):723-8. PubMed ID: 23615295
[TBL] [Abstract][Full Text] [Related]
59. Monitoring unfractionated heparin therapy. 4 hour-stability of anti-Xa activity in unspun citrated tubes.
Toulon P; Appert-Flory A; Fischer F; Buvat S; Jambou D; Mahagne MH
Thromb Res; 2020 Feb; 186():7-12. PubMed ID: 31837560
[TBL] [Abstract][Full Text] [Related]
60. Monitoring unfractionated heparin in pediatric patients with congenital heart disease having cardiac catheterization or cardiac surgery.
Kim GG; El Rouby S; Thompson J; Gupta A; Williams J; Jobes DR
J Thromb Thrombolysis; 2010 May; 29(4):429-36. PubMed ID: 19714446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
